Cancer Insight

oa Open Access

E-ISSN: 2972-3388

Cancer Insight (CI) is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer.  Cancer Insight aims to disseminate and communicate scientific advancement and impactful discoveries on the field of oncology to researchers, academics, clinicians, and the public worldwide. 

View full aims & scope

Journal Browser
Journal Insights

Frequency: Half-yearly                    

Time to first decision: 2.4 Weeks

Submission to publication: 4 Weeks        

Acceptance rate: 26%

ISSN: 2972-3388

Latest Articles More >>
Open Access Journal Article
Comprehensive analyses reveal molecular and clinical characteristics of RNA modification writers across 32 cancer types
by Jiayu Ding , Hao Shen , Jiaying Ji , Jiaxing Li , Wenbin Kuang , Zhongrui Shi , Dawei Wang , Yuanyuan Chen , Didi Wan , Xiao Wang  and  Peng Yang
CI  2024, 36; 3(2), 36; 10.58567/ci03020004 - 25 January 2024
Abstract
Adenosine alterations to RNA, which are largely determined by RNA modification writers (RMWs), are critical for cancer growth and progression. These RMWs can catalyze different types of adenosine modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), alternative polyadenylation (APA), and adenosine-to-inosine (A-to-I) RNA editing. These modifications have pr [...] Read more

Open Access Journal Article
A prognostic aging-related lncRNA risk model correlates with the immune microenvironment in HCC
by Kun Mei , Zilu Chen , Qin Wang , Akbar Ali , Yan Huang  and  Luo Yi
CI  2024, 35; 3(2), 35; 10.58567/ci03020003 - 09 January 2024
Abstract
Background: Hepatocellular carcinoma (HCC) stands out as one of the most lethal cancers globally, given its complexity, recurrence following surgical resection, metastatic potential, and inherent heterogeneity. In recent years, researchers have systematically elucidated the significance of long non-coding RNA (lncRNA) in the initiation and progression of HCC. The intr [...] Read more
Show Figures

Open Access Journal Article
Correlation between the immune microenvironment and bladder cancer based on a prognostic miRNA risk model
by Kun Mei , Zilu Chen , Le Huang , Joyce Wang  and  Yong Wei
CI  2024, 34; 3(2), 34; 10.58567/ci03020002 - 04 January 2024
Abstract
Background: Bladder cancer (BLCA), particularly invasive BLCA, has become a medical burden worldwide as it is associated with recurrence and easy metastasis. There are specific differences in the expression of various miRNAs in tumor and normal tissues. Hence, miRNAs can be used as biomarkers for tumor diagnosis and prognostic evaluation. The current study aimed to predict the [...] Read more

Open Access Review
CRISPR-Cas9 Unleashed: Gene-Slicing Adventures in the Cancer Battlefield
by Shivakumar Sonnaila  and  Shilpi Agrawal
CI  2024, 33; 2(2), 33; 10.58567/ci02020008 - 02 January 2024
Abstract
Cancer, a global health menace, continues to pose significant challenges in terms of incidence and mortality, necessitating innovative therapeutic strategies. Despite existing treatments, the limitations persist, prompting a quest for novel approaches. The emergence of immunotherapy marked a transformative era in solid tumor treatments, yet its efficacy is constrained by advers [...] Read more
Show Figures

Open Access Review
Exploring Longitudinal MRI-Based Deep Learning Analysis in Parkinson’s Patients - A Short Survey Focus on Handedness
by Yuan Gu , Ziyang Wang , Yuli Wang , Yishu Gong  and  Chen Li
CI  2023, 32; 3(1), 32; 10.58567/ci03010006 - 28 December 2023
Abstract
Parkinson’s Disease (PD) is a prevalent progressive neurodegenerative condition affecting millions globally. Research has found that individuals with PD have a reduced risk of certain cancers, such as colon, lung, and rectal cancers, but an increased risk of brain cancer. Therefore, there is an urgent need for the development of advanced PD diagnostic methods and for inve [...] Read more

Open Access Review
Research progress of nanomedicine for tumor immunotherapy
by Xingyi Wan , Mengyan Jiang  and  Shriya Madan
CI  2023, 31; 3(1), 31; 10.58567/ci03010005 - 28 December 2023
Abstract
Cancer, a pervasive threat to human health, presents formidable challenges to traditional treatment approaches. Tumor immunotherapy has emerged as a promising strategy for combating malignancies by bolstering the body's immune response to thwart tumor metastasis and recurrence. Nonetheless, the intricacies of tumors, patient heterogeneity, and the presence of tumor-immunosuppre [...] Read more
Show Figures

Open Access Journal Article
LTBP1 promotes the progression of triple negative breast cancer via activating the RhoA/ROCK signaling pathway
by Jingcheng Zhang , Hong Deng  and  Jun Wang
CI  2023, 30; 3(2), 30; 10.58567/ci03020001 - 26 December 2023
Abstract
The latent transforming growth factor-beta (TGF-β) binding protein 1 (LTBP1) has been implicated in various cellular processes, but its role in triple-negative breast cancer (TNBC) remains unclear. In this study, we investigated the impact of LTBP1 on TNBC progression and its underlying mechanisms. Analysis of online datasets revealed elevated LTBP1 mRNA expression in brea [...] Read more

Open Access Review
Overcoming MTDH and MTDH-SND1 complex: driver and potential therapeutic target of cancer
by Hao Shen , Jiayu Ding , Jiaying Ji , Binjian Jiang , Xiao Wang  and  Peng Yang
CI  2023, 29; 3(1), 29; 10.58567/ci03010004 - 11 December 2023
Abstract
Metadherin (MTDH), also known as LYRIC or AEG-1, is an oncogene that enhances tumor progression, metastasis, drug resistance, and immune escape in various cancers by modulating multiple oncogenic pathways, including NF-κB, PI3K/AKT, Wnt/β-catenin, MAPK, and AMPK. Due to the unknown of the complete structure of MTDH, the deep mechanisms of MTDH and selective inhibitor [...] Read more
Show Figures

Open Access Review
Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity
by Sindhu Ramesh , Peyton Johnson , Khalda Fadlalla , Austin Moore , Chung-Hui Huang , Kristy Berry , Yulia Y Maxuitenko , Xi Chen , Adam B Keeton , Gang Zhou  and  Gary Piazza
CI  2023, 28; 3(1), 28; 10.58567/ci03010003 - 30 November 2023
Abstract
Approximately 28 million individuals in the United States face the risk of developing precancerous colonic adenomas (polyps) and potentially progressing to colorectal cancer (CRC). While a promising strategy for CRC prevention involves pharmacological intervention, such as cancer chemoprevention or interception, currently, there are no FDA-approved drugs capable of preventing t [...] Read more
Show Figures

Open Access Review
Reassessing specificity/selectivity of taxane-based chemotherapy
by Elizabeth R. Smith , Zheshen Li , Zhe-Sheng Chen  and  Xiang-Xi Xu
CI  2023, 27; 3(1), 27; 10.58567/ci03010002 - 29 November 2023
Abstract
The paramount prerequisite for effective anti-cancer drugs is their ability to eradicate malignant cells while sparing non-cancer cells. The divergence in properties between malignant and non-cancer cells establishes a "therapeutic window," a critical consideration for achieving desirable treatment outcomes. Central to this is the imperative of a cancer drug's "selectivity and [...] Read more
Show Figures